​

Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Kymera Therapeutics Ownership Summary

Kymera Therapeutics is owned by 36.08% institutional investors, 2.08% insiders, and 61.84% retail investors. Fmr is the largest institutional shareholder, holding 13.86% of KYMR shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.55% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKymera Therapeutics36.08%2.08%61.84%
SectorHealthcare Stocks 35.64%12.08%52.28%
IndustryBiotech Stocks 35.26%12.00%52.74%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr11.70M13.86%$974.49M
Baker bros. advisors lp8.66M10.26%$721.06M
Avoro capital advisors7.47M8.86%$622.57M
Price t rowe associates inc /md/6.06M7.18%$504.81M
Vanguard group6.27M7.18%$487.69M
Bvf inc/il5.50M6.52%$458.32M
T. rowe price investment management5.46M6.48%$455.18M
Blackrock funding, inc. /de5.06M6.00%$421.52M
Blackrock4.16M5.87%$124.04M
Atlas venture life science advisors4.58M5.42%$381.30M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors4.58M48.26%$381.30M
Merck772.16K18.40%$64.31M
Bvf inc/il5.50M14.60%$458.32M
Siren3.19M7.36%$265.43M
Aquilo capital management138.52K6.80%$3.79M
Avoro capital advisors7.47M6.12%$622.57M
Aju ib investment19.65K5.36%$1.64M
Baker bros. advisors lp8.66M4.14%$721.06M
Octagon capital advisors lp425.00K3.92%$35.40M
Commodore capital lp750.00K3.61%$62.47M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management5.46M0.31%4.84M
Fmr11.70M0.05%2.77M
Vanguard group6.27M0.01%845.92K
Blackrock4.16M0.00%499.77K
Vanguard fiduciary trust427.38K0.01%427.38K

Top Sellers

HolderShares% AssetsChange
Redmile group---803.29K
Deep track capital, lp---600.33K
Wellington management group llp3.89M0.06%-523.25K
Avidity partners management lp---500.00K
First light asset management---383.31K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust427.38K0.01%427.38K$35.60M
Freestone grove partners lp156.76K0.09%156.76K$13.06M
Connor, clark & lunn investment management104.28K0.02%104.28K$8.69M
Axa investment managers80.53K0.01%80.53K$4.56M
Fifth third bancorp51.24K0.01%51.24K$4.27M

Sold Out

HolderChange
Dunhill financial-1.00
Global financial private client-1.00
Vermillion wealth management-1.00
Financial gravity asset management-2.00
Capital performance advisors llp-3.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026169-35.74%30,451,270-66.11%360.34%100-40.12%40-37.50%
Dec 31, 2025177-17.67%47,762,207-40.94%540.64%117-4.10%37-31.48%
Sep 30, 2025208-0.95%79,891,0442.85%991.07%117-10.00%536.00%
Jun 30, 202521518.78%78,776,9568.20%971.19%13248.31%52-7.14%
Mar 31, 202520-89.07%22,191,205-69.06%270.31%7-92.39%4-93.10%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.92M3.55%67.99K
Fidelity Growth Compy Commingled Pl O2.24M3.46%52.60K
T. Rowe Price New Horizons2.26M2.74%311.10K
Fidelity Growth Company Fund2.19M2.66%49.00K
Vanguard Total Stock Mkt Idx Inv2.09M2.54%-2.72K
US Small-Cap Growth II Equity Comp1.95M2.38%-18.26K
Vanguard US Total Market Shares ETF1.54M2.38%1.91K
Vanguard Health Care Inv1.80M2.18%-375.38K
iShares Russell 2000 ETF1.62M1.97%9.60K
Vanguard Small Cap Index1.51M1.83%5.03K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 07, 2026Mainolfi Nello Chief Executive OfficerSell$5.95M
Jun 30, 2026Jacobs Bruce N. Chief Financial OfficerSell$469.31K
Jun 30, 2026Jacobs Bruce N. Chief Financial OfficerSell$165.81K
Jun 30, 2026Jacobs Bruce N. Chief Financial OfficerSell$189.66K
Jun 30, 2026Jacobs Bruce N. Chief Financial OfficerSell$124.07K

Insider Transactions Trends

DateBuySell
2026 Q3-7
2026 Q2-182
2026 Q1-47
2025 Q4238
2025 Q3-2

KYMR Ownership FAQ

Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 36.08%, followed by 2.08% insiders and 61.84% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 35.26%, which Kymera Therapeutics exceeds.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Fmr (11.7M shares, 13.86%), Baker bros. advisors lp (8.66M shares, 10.26%), and Avoro capital advisors (7.47M shares, 8.86%). Together, they hold 32.98% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 48.26% of its assets in 4.58M Kymera Therapeutics shares, valued at 381.3M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Kymera Therapeutics shares, with 3.55% of its total shares outstanding invested in 2.92M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools